Christine Y Lu1, Fang Zhang2, Anita K Wagner2, Larissa Nekhlyudov3, Craig C Earle4, Matthew Callahan2, Robert LeCates2, Xin Xu2, Dennis Ross-Degnan2, J Frank Wharam2. 1. Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 401 Park Drive, Suite 401 East, Boston, MA, 02215, USA. christine_lu@harvardpilgrim.org. 2. Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 401 Park Drive, Suite 401 East, Boston, MA, 02215, USA. 3. Department of Medicine, Brigham & Women's Hospital, 800 Huntington Avenue, Boston, MA, 02115, USA. 4. Ontario Institute for Cancer Research, 661 University Avenue, Toronto, ON, Canada.
Abstract
OBJECTIVE: High-deductible health plans (HDHPs) have become the predominant commercial health insurance arrangement in the US. HDHPs require substantial out-of-pocket (OOP) costs for most services but often exempt medications from high cost sharing. We examined effects of HDHPs on OOP costs and utilization of adjuvant hormonal therapy (AHT), which are fundamental care for patients with breast cancer. METHODS: This controlled quasi-experimental study used claims data (2003-2012) from a large national health insurer. We included 986 women with incident early-stage breast cancer, age 25-64 years, insured by employers that mandated a transition from low-deductible (≤ $500/year) to high-deductible (≥ $1000/year) coverage, and 3479 propensity score-matched controls whose employers offered only low-deductible plans. We examined AHT utilization and OOP costs per person-year before and after the HDHP switch. RESULTS: At baseline, the OOP costs for AHT were $40.41 and $36.55 per person-year among the HDHP and control groups. After the HDHP switch, the OOP costs for AHT were $91.76 and $72.98 per person-year among the HDHP and control groups, respectively. AHT OOP costs increased among HDHP members relative to controls but the change was not significant (relative change 13.72% [95% CI - 9.25, 36.70%]). AHT use among HDHP members did not change compared to controls (relative change of 2.73% [95% CI - 14.01, 19.48%]); the change in aromatase inhibitor use was - 11.94% (95% CI - 32.76, 8.88%) and the change in tamoxifen use was 20.65% (95% CI - 8.01, 49.32%). CONCLUSION: We did not detect significant changes in AHT use after the HDHP switch. Findings might be related to modest increases in overall AHT OOP costs, the availability of low-cost generic tamoxifen, and patient awareness that AHT can prolong life and health. Minimizing OOP cost increases for essential medications might represent a feasible approach for maintaining medication adherence among HDHP members with incident breast cancer.
OBJECTIVE: High-deductible health plans (HDHPs) have become the predominant commercial health insurance arrangement in the US. HDHPs require substantial out-of-pocket (OOP) costs for most services but often exempt medications from high cost sharing. We examined effects of HDHPs on OOP costs and utilization of adjuvant hormonal therapy (AHT), which are fundamental care for patients with breast cancer. METHODS: This controlled quasi-experimental study used claims data (2003-2012) from a large national health insurer. We included 986 women with incident early-stage breast cancer, age 25-64 years, insured by employers that mandated a transition from low-deductible (≤ $500/year) to high-deductible (≥ $1000/year) coverage, and 3479 propensity score-matched controls whose employers offered only low-deductible plans. We examined AHT utilization and OOP costs per person-year before and after the HDHP switch. RESULTS: At baseline, the OOP costs for AHT were $40.41 and $36.55 per person-year among the HDHP and control groups. After the HDHP switch, the OOP costs for AHT were $91.76 and $72.98 per person-year among the HDHP and control groups, respectively. AHT OOP costs increased among HDHP members relative to controls but the change was not significant (relative change 13.72% [95% CI - 9.25, 36.70%]). AHT use among HDHP members did not change compared to controls (relative change of 2.73% [95% CI - 14.01, 19.48%]); the change in aromatase inhibitor use was - 11.94% (95% CI - 32.76, 8.88%) and the change in tamoxifen use was 20.65% (95% CI - 8.01, 49.32%). CONCLUSION: We did not detect significant changes in AHT use after the HDHP switch. Findings might be related to modest increases in overall AHT OOP costs, the availability of low-cost generic tamoxifen, and patient awareness that AHT can prolong life and health. Minimizing OOP cost increases for essential medications might represent a feasible approach for maintaining medication adherence among HDHP members with incident breast cancer.
Entities:
Keywords:
Adjuvant hormonal therapy; Aromatase inhibitors; Breast cancer care; High-deductible health insurance; Tamoxifen
Authors: Christine Y Lu; Alyce S Adams; Dennis Ross-Degnan; Fang Zhang; Yuting Zhang; Carl Salzman; Stephen B Soumerai Journal: Psychiatr Serv Date: 2011-02 Impact factor: 3.084
Authors: Jennifer C Livaudais; Dawn L Hershman; Laurel Habel; Lawrence Kushi; Scarlett Lin Gomez; Christopher I Li; Alfred I Neugut; Louis Fehrenbacher; Beti Thompson; Gloria D Coronado Journal: Breast Cancer Res Treat Date: 2011-09-16 Impact factor: 4.872
Authors: Sheila K Reiss; Dennis Ross-Degnan; Fang Zhang; Stephen B Soumerai; Alan M Zaslavsky; J Frank Wharam Journal: Health Serv Res Date: 2011-03-17 Impact factor: 3.402
Authors: Ann B Nattinger; Purushottam W Laud; Ruta Bajorunaite; Rodney A Sparapani; Jean L Freeman Journal: Health Serv Res Date: 2004-12 Impact factor: 3.402
Authors: J Frank Wharam; Alison A Galbraith; Ken P Kleinman; Stephen B Soumerai; Dennis Ross-Degnan; Bruce E Landon Journal: Ann Intern Med Date: 2008-05-06 Impact factor: 25.391
Authors: Nancy Krieger; Jarvis T Chen; Pamela D Waterman; David H Rehkopf; S V Subramanian Journal: Am J Public Health Date: 2003-10 Impact factor: 9.308
Authors: J Frank Wharam; Fang Zhang; Bruce E Landon; Robert LeCates; Stephen Soumerai; Dennis Ross-Degnan Journal: Med Care Date: 2016-05 Impact factor: 2.983
Authors: F E Alexander; T J Anderson; H K Brown; A P Forrest; W Hepburn; A E Kirkpatrick; C McDonald; B B Muir; R J Prescott; S M Shepherd Journal: Br J Cancer Date: 1994-09 Impact factor: 7.640
Authors: Ronald M Kline; Neeraj K Arora; Cathy J Bradley; Eden R Brauer; Darci L Graves; Natasha Buchanan Lunsford; Mary S McCabe; Shelley Fuld Nasso; Larissa Nekhlyudov; Julia H Rowland; Rebekkah M Schear; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2018-12-01 Impact factor: 13.506
Authors: Barbara Pistilli; Angelo Paci; Arlindo R Ferreira; Antonio Di Meglio; Vianney Poinsignon; Aurelie Bardet; Gwenn Menvielle; Agnes Dumas; Sandrine Pinto; Sarah Dauchy; Leonor Fasse; Paul H Cottu; Florence Lerebours; Charles Coutant; Anne Lesur; Olivier Tredan; Patrick Soulie; Laurence Vanlemmens; Christelle Jouannaud; Christelle Levy; Sibille Everhard; Patrick Arveux; Anne Laure Martin; Alexandra Dima; Nancy U Lin; Ann H Partridge; Suzette Delaloge; Stefan Michiels; Fabrice André; Ines Vaz-Luis Journal: J Clin Oncol Date: 2020-06-22 Impact factor: 44.544
Authors: Catherine Goetzinger; Caroline Alleaume; Anna Schritz; Bernard Vrijens; Marie Préau; Guy Fagherazzi; Laetitia Huiart Journal: Front Pharmacol Date: 2022-09-27 Impact factor: 5.988